stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) EPS (diluted)
Haemonetics Corporation's EPS (diluted) for fiscal 2026 was $2.05, down 38.1% from $3.31 in fiscal 2025. Over the twelve months to 30 September 2026 it was $2.23. Over the past ten years it has ranged from −$1.09 (fiscal 2016) to $3.31 (fiscal 2025); the current reading is higher than 75% of that period. Haemonetics Corporation ranks 20th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | $2.05 | (38.07%) |
| FY2025 | $3.31 | 44.54% |
| FY2024 | $2.29 | 2.23% |
| FY2023 | $2.24 | 166.67% |
| FY2022 | $0.84 | (45.81%) |
| FY2021 | $1.55 | 4.73% |
| FY2020 | $1.48 | 42.31% |
| FY2019 | $1.04 | 22.35% |
| FY2018 | $0.85 | — |
| FY2017 | −$0.51 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.00 | 38.89% |
| Jun 2026 | $0.72 | — |
| Mar 2026 | −$0.44 | — |
| Dec 2025 | $0.95 | 17.28% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | $37.97 |
| BIO Bio-Rad Laboratories, Inc. compare | $37.97 |
| LIVN LivaNova PLC compare | $3.49 |
| ITGR Integer Holdings Corporation compare | $2.98 |
| HAE Haemonetics Corporation | $2.23 |
| TXG 10x Genomics compare | −$0.59 |
| AXGN AxoGen, Inc. compare | −$0.65 |
| BRKR Bruker Corporation compare | −$1.01 |
| IRTC iRhythm Holdings, Inc. compare | −$1.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on HAE
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement